Novartis Ag

Misonix, Inc.

Christopher Bush

Theodore A D Novak

Fabian Chen

Gesine Winzenburg

Surya Prakash Ayalasomayajula

Masha Berkhin

Bernd Trueby

Theodore AD Novak

Theodore Ad Novak

The present invention relates to a solid unit oral dosage form comprising sacubitril and valsartan in a 1:1 molar ratio, preferably in the form of the so-called angiotensin receptor neprilysin inhibitor (ARNI) LCZ696, which is a complex salt hydrate of sacubitril, valsartan, and sodium ions, appropriate for use in pediatrics or other patients where low and individual dosing is required or who encounter problems with swallowing e.g. as a result of a disease or because of age, to the manufacture of said solid dosage form and to invention embodiments relating to therapy using said dosage form.

Galenic formulations of organic compounds

An ultrasonic probe includes a shaft having a longitudinal axis and a head disposed at a distal end of the shaft. The head has a cylindrical lateral surface and an end face oriented perpendicularly to the axis. The head has three shaping surfaces at a distal end of the cylindrical surface, each shaping surface extending at an acute angle to the axis. Each of the shaping surfaces intersects or is contiguous with both the cylindrical surface and the end face.

Ultrasonic wound debrider probe and method of use

Growing community of inventors

East Hanover, NJ, United States of America

Christopher Bush